News|Articles|November 18, 2026

FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer

Fact checked by: Maggie L. Shaw
Listen
0:00 / 0:00

Key Takeaways

  • FDA authorized giredestrant plus everolimus for ER-positive/HER2-negative, ESR1-mutated advanced breast cancer after endocrine therapy failure, requiring ESR1 detection via an FDA-authorized assay.
  • evERA showed 62% reduction in progression/death risk in ESR1-mutated tumors (HR 0.38), with median PFS 10.0 vs 5.5 months versus endocrine therapy plus everolimus.
SHOW MORE

An oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer.

An all-oral regimen of giredestrant (Wilserdly; Genentech), a next-generation selective estrogen receptor degrader (SERD), plus everolimus is now FDA approved for adults with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative, ESR1-mutated locally advanced or metastatic breast cancer.1

"For patients with ESR1-mutated advanced breast cancer, the development of resistance to endocrine therapy remains a substantial challenge—often requiring more intensive treatment,” said Levi Garraway, MD, PhD, chief medical officer and head of global product development, Genentech, in a statement. “By pairing potent estrogen receptor degradation with everolimus, Wilserdly offers a targeted, all-oral regimen that significantly delays disease progression and allows advanced breast cancer patients to take their treatment from home.”

The approval, announced November 16, 2026, covers patients whose disease recurred during or after completion of endocrine-based adjuvant therapy or progressed on at least 1 endocrine-based regimen in the metastatic setting. The ESR1 mutation must be detected by an FDA-authorized test. Genentech said the drug is expected to be available in the US in the coming weeks.

Lower Risk of Progression in ESR1-Mutated Disease

The approval is based on the phase 3 evERA Breast Cancer trial (NCT05306340), which compared giredestrant plus everolimus with standard endocrine therapy plus everolimus in patients whose disease had progressed after prior cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy. Among patients with ESR1-mutated tumors, the giredestrant combination reduced the risk of disease progression or death by 62% (stratified HR, 0.38; 95% CI, 0.27-0.54; P < .0001).

Results published in The New England Journal of Medicine showed a median progression-free survival (PFS) of 10.0 months with the giredestrant regimen vs 5.5 months with the comparator in the ESR1-mutated population.2 In the intention-to-treat (ITT) population, a co-primary end point, median PFS was 8.8 vs 5.5 months (HR, 0.56; 95% CI, 0.44-0.71). Overall survival data were immature at the time of analysis but trended in favor of the giredestrant combination in both the ITT (HR, 0.69; 95% CI, 0.47-1.00) and ESR1-mutated (HR, 0.62; 95% CI, 0.38-1.02) populations.

Bradycardia Among Key Safety Warnings

Warnings and precautions for giredestrant include bradycardia and embryo-fetal toxicity.3 Females of reproductive potential should use effective nonhormonal contraception during treatment and for 2 weeks after the last dose, and male patients with female partners of reproductive potential should use effective contraception for the same period. The most common adverse reactions (≥20%), including laboratory abnormalities, were decreased hemoglobin, lymphocytes, white blood cells, neutrophils, platelets, calcium, potassium, and sodium; increased aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine; stomatitis; rash; fatigue; diarrhea; musculoskeletal pain; pneumonitis; and nausea. Patients should avoid grapefruit and grapefruit juice, and concomitant use with strong CYP3A inhibitors or inducers should be avoided.

On access, Genentech said commercially insured patients may pay as little as $0 through co-pay assistance, and its Genentech Access Solutions program offers a bridge program for patients facing insurance delays.1

Adjuvant Decision Expected by November 30

The FDA also granted a priority review to giredestrant as adjuvant therapy, with a decision date of November 30, 2026. That application is based on the phase 3 lidERA trial (NCT04961996), which compared giredestrant with standard endocrine therapy in adults with ER-positive, HER2-negative stage I-III breast cancer at intermediate to high risk of recurrence. Genentech said an approval would make giredestrant the first new adjuvant endocrine therapy in more than 20 years.

“Patients with advanced breast cancer progressing on endocrine therapies often face difficult choices and deteriorating quality of life as options narrow,” said Erica L. Mayer, MD, MPH, director of breast cancer clinical research at the Dana-Farber Cancer Institute, in a statement.1 “The evERA trial demonstrates that the oral giredestrant combination regimen directly targets the primary genomic drivers of resistance, offering patients prolonged disease control through a fully oral therapeutic option.”

References

  1. FDA approves Genentech's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer. News release. Genentech. November 16, 2026. Accessed November 18, 2026. https://www.gene.com/media/press-releases/15144/2026-11-16/fda-approves-genentechs-wilserdly-girede
  2. Mayer E, Tolaney SM, Martin M, et al. Giredestrant plus everolimus in advanced breast cancer. N Engl J Med. 2026;395(13):1285-1298. doi:10.1056/NEJMoa2602457
  3. Wilserdly (giredestrant) capsules, for oral use. Prescribing information. Genentech USA, Inc; 2026. Accessed November 18, 2026. https://www.gene.com/download/pdf/wilserdly_prescribing.pdf

Related to this article